The investment is part of SAFC’s worldwide facilities initiative and is designed to better serve the biopharmaceutical industry by creating ‘Centers of Excellence’ for manufacturing and supply chain
Invida is expected to be in charge of filing and commercialising the drugs in different countries. The agreement is for an initial period of five years renewable for
The histamine H3 receptor is a drug target of high interest because of evidence that blocking this receptor in the brain can improve cognition, alertness and attention. H3
According to the scientists, based on the measurement of cell-associated CD4 protein in whole blood samples such as a finger prick, the kit will enable patients to receive
Reportedly, the approval is based on the on subgroup data from Jupiter study, which evaluated the impact of rosuvastatin 20mg on reducing major cardiovascular events in a previously
PPD said that the new facility will offer product and analytical development services, including method development; validation; stability, release and quality control testing; and global clinical supplies services,
The collaborative program is expected to encompass training for Johns Hopkins researchers in the NYSCF laboratory in Manhattan, specific research collaborations and a NYSCF fellowship to support Johns
Under the terms of the agreement Antares and Uman will invest jointly to develop and commercialize Vibex MTX, Antares’ new pressure-assisted, injection device, containing methotrexate (MTX) for rheumatoid
Protalix BioTherapeutics said that it has made the submission in response to a request from the FDA for validation data from its upgraded manufacturing facility. The FDA is
Debiopharm Group said that the trial will evaluate the maximum tolerated dose and safety of Debio 0932 in patients suffering from advanced solid tumours or lymphoma. Debio 0932
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.